Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
atopic dermatitis
Biotech
Anaptys scraps atopic dermatitis asset after ph. 2 fail
ANB032 failed to reduce eczema area and itch severity in a phase 2b trial, missing all of its endpoints.
Darren Incorvaia
Dec 11, 2024 11:02am
Q32's stock plunges in wake of anti-IL-7R antibody's eczema fail
Dec 11, 2024 8:25am
Enveda envisions clinical wins with $130M series C raise
Nov 21, 2024 10:55am
Rapt's share price sinks after shelving AD drug under FDA hold
Nov 11, 2024 9:44am
Amgen reports first phase 3 win for $400M eczema drug
Sep 25, 2024 5:50am
Connect reduces China workforce, mulls strategy for asthma drug
Sep 6, 2024 4:37am
